



Shionogi Announces Corporate Reorganization and Personnel Reassignment (Effective April 1, 2026)

OSAKA, Japan, February 13, 2026 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "SHIONOGI") announces that it will implement the following corporate reorganization and personnel reassignment, effective April 1, 2026.

1. Corporate Reorganization

- Division to consolidate post-marketing regulatory operations.
- A Sales Promotion Department will be established under the Integrated Disease Care Division, separating domestic product marketing functions from the current New Product Planning Department.
- The New Product Planning Department under the Integrated Disease Care Division will be renamed the Global New Product Planning Department.
- The Digital Marketing Office under the Integrated Disease Care Division will be renamed the Marketing Support Office.

2. Personnel Reassignments

Name	New Position	Current Position
Healthcare Business Supervisory Unit		
Pharmaceutical Commercial Division		
Akihiro Fujimaki	Head of Sales Promotion Department	Promotion Department - Region 3
Integrated Disease Care Division		
Atsushi Sano	Head of Product Marketing Department	Head of Sales Promotion Department
Hiroaki Itoh	Head of Global New Product Planning Department	Head of New Product Planning Department
Kenji Kuroda	Head of Marketing Support Office	Head of Digital Marketing Office
Corporate Supervisory Unit		
Corporate Quality Assurance and Ethics & Compliance Management Division		
Miki Hosoi	Head of Post-Marketing Regulatory Affairs Office	Regulatory Affairs Department
DX Promotion Division		
Kinichi Imura	Head of DX New Business Promotion Office	DX New Business Promotion Office

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause

actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>